Abstract
Near-infrared (NIR) spectroscopy was used to measure blood oxygen saturation (SO2)in vivo, in normal rat brain and in subcutaneously-implanted rat 9L gliosarcoma. Changes in cranial and tumor blood SO2 were measured during lethal pentobarbital overdose. After sacrifice, SO2 of cranial blood fell rapidly to a mean of 5.0% of the pre-sacrifice values, whereas SO2 of tumor blood stabilized at a mean of 72.4% of the pre-sacrifice values. This suggests that oxygen consumption by tumor is very low compared to brain. Cranial blood had a higher SO2 than tumor blood before sacrifice (p=0.03), and a lower SO2 after sacrifice (p=0.02). The magnitude of the change in SO2 after sacrifice was greater in normal brain than in tumor (p=0.02), showing that brain tissue uses a greater proportion of the oxygen in ischemic blood than does tumor tissue.
To determine the effect of carmustine (BCNU) treatment on tumor and cranial blood SO2, we compared BCNU-treated rats with sham-treated rats. Continuous NIR measurements before and immediately following treatment (ie. over 30–60 min) showed that tumor blood SO2 tended to increase after BCNU treatment, whereas SO2 tended to decrease following sham-treatment. The difference in SO2 between treated and control tumors was significant at 60 min (p=0.02). Thus BCNU treatment can potentially result in immediate increases in tumor oxygenation. The increase in treated tumor blood SO2 occurred despite the fact that there was no change in cranial blood SO2 even at day 4 following treatment. Tumor blood SO2 was inversely correlated with tumor size (p=0.001), confirming that blood is more poorly oxygenated in large tumors.
Similar content being viewed by others
References
Mitchell JB, Glatstein E: Radiation oncology: past achievements and ongoing controversies. Cancer Res 51: 5065s-5073s, 1991
Weinstein JN, Kohn KW, Grever MR, Viswanadhan VN, Rubinstein LV, Monks AP, Scudiero DA, Welch L, Koutsoukos AD, Chiausa AJ, Pauli KD: Neural computing in cancer drug development: predicting mechanism of action. Science 258: 447–451, 1992
Teicher BA, Herman TS, Holden SA, Wang Y, Pfeffer MR, Crawford JW, Frei III E: Tumor resistance to alkylating agents conferred by mechanisms operative onlyin vivo. Science 247: 1457–1461, 1990
Steen RG: Edema and tumor perfusion: characterization by quantitative1H magnetic resonance imaging. Am J Roentgenol 158: 259–264, 1992
Hampson NB, Piantodosi SA: Near-infrared monitoring of human skeletal muscle oxygenation during forearm ischemia. J Appl Physiol 64: 2449–2457, 1988
Glaister DH, Miller NL: Cerebral tissue oxygen status and psychomotor performance during lower body negative pressure (LBNP). Aviat Space Environ Med 61: 99–105, 1990
Bacon DS, Afifi MS, Griebel JA, Camporesi EM: Cerebrocortical oxygenation and ventilatory response during sustained hypoxia. Resp Physiol 80: 245–258, 1990
Hampson NB, Camporesi EM, Stolp BW, Moon RE, Shook JE, Griebel JA, Piantodosi CA: Cerebral oxygen availability by NIR spectroscopy during transient hypoxia in humans. J Appl Physiol 69: 907–913, 1990
Steen RG, Wilson DA, Bowser C, Rajan SS, Wehrle JP, Glickson JD:31P NMR spectroscopic and near-infrared spectrophotometric studies of effects of anesthetics onin vivo RIF-1 tumors: relationship to tumor radiosensitivity. NMR in Biomed 2: 87–92, 1989
Sostman HD, Rockwell S, Sylvia AL, Madwed D, Cofer G, Charles HC, Negro-Vilar R, Moore D: Evaluation of BA1112 rhabdomyosarcoma oxygenation with microelectrodes, optical spectrophotometry, radiosensitivity, and magnetic resonance spectroscopy. Magn Reson Med 20: 253–267, 1991
Steen RG, Graham MM:31P magnetic resonance spectroscopy is sensitive to tumor hypoxia: perfusion and oxygenation of rat 9L gliosarcoma after treatment with BCNU. NMR in Biomed 4: 117–124, 1991
Steen RG, Tamargo RJ, McGovern KA, Rajan SS, Brem H, Wehrle JP, Glickson JD:In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effects of tumor growth and treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea on tumor bioenergetics and histology. Cancer Res 48: 676–681, 1988
Bullard DE, Schold SC, Bigner SH, Bigner DD: Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol 40: 410–427, 1981
Kitai T, Tanaka A, Tokuka A, Tanaka K, Yamaoka I, Ozawa K, Hirao K: Quantitative detection of hemoglobin saturation in the liver by near infrared spectroscopy. J Hepatol, 1993 (in press)
Hazeki O, Tamura M: The quantitative analysis of hemoglobin oxygenation state of rat brainin situ as monitored by infrared spectroscopy. J Appl Physiol 64: 796–802, 1988
Gray LH, Steadman JM: Determination of the oxyhaemoglobin dissociation curves for mouse and rat blood, J Physiol 175: 161–171, 1964
Crumrine RC, LaManna JC: Regional cerebral metabolites, blood flow, plasma volume, and mean transit time in total cerebral ischemia in the rat. J Cerebr Blood Flow Metab 11: 272–282, 1991
Kleinschmidt-DeMasters BK: Intracarotid BCNU leukoencephalopathy. Cancer 57: 1276–1280, 1986
Burger PC, Kamenar E, Schold SC, Fay JW, Phillips GL, Herzig GP: Encephalomyopathy following high-dose BCNU therapy. Cancer 48: 1318–1327, 1981
DeChiro G, Oldfield E, Wright DC, DeMichele D, Katz DA, Patronas NJ, Doppman JL, Larson SM, Ito M, Kufta CV: Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. Am J Roentgenol 150: 189–197, 1988
DeWys WD, Fowler EH: Report of vasculitis and blindness after intracarotid injection of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in dogs. Cancer Chemother Rep 57: 33–40, 1973
Omojola MF, Fox AJ, Auer RN, Vinuela FV: Hemorrhagic encephalitis produced by selective non-occlusive intracarotid BCNU injection in dogs. J Neurosurg 57: 791–796, 1982
Clayton PE, Shalet SM, Price DA, Campbell RHA: Testicular damage after chemotherapy for childhood brain tumors. J Pediatr 112: 922–926, 1988
Arnold DL, Shoubridge EA, Feindel W, Villemure JG: Metabolic changes in cerebral gliomas within hours of treatment with intra-arterial BCNU demonstrated by phosphorus magnetic resonance spectroscopy. Can J Neurol Sci 14: 570–575, 1987
Steen RG, Tamargo RJ, Brem H, Glickson JD, Wehrle JP:In vivo 31P nuclear magnetic resonance spectroscopy of rat 9L gliosarcoma treated with BCNU: dose-response of spectral changes. Magn Reson Med 11: 258–266, 1989
Fross RD, Warnke PC, Groothuis DR: Blood flow and blood-to-tissue transport in 9L gliosarcoma: the role of the brain tumor model in drug delivery research. J Neuro-Oncol 11: 185–197, 1991
Memezawa H, Katayama Y, Shimizu J, Suzuki S, Kashiwagi F, Kamiya T, Terashi A: Effects of Fluosol-DA on brain edema, energy metabolites, and tissue oxygen content in acute cerebral ischemia. Adv Neurol 52: 109–118, 1990
Wong K-H, Wallen CA, Wheeler KT: Biodistribution of misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in rats bearing unclamped and clamped 9L subcutaneous tumors. Int J Radiat Oncol Biol Phys 17: 135–143, 1989
Nomura K, Hoshino T, Knebel K, Deen DF, Barker M: BCNU-induced perturbations in the cell cycle of 9L rat brain tumor cells. Cancer Treat Rep 62: 747–754, 1978
Chaplin DJ: The effect of therapy on tumour vascular function. Int J Radiat Biol 60: 311–325, 1991
Constantinidis I, Braunschweiger PG, Wehrle JP, Kumar N, Johnson CS, Furmanski P, Glickson JD:31P nuclear magnetic resonance studies of the effect of recombinant human Interleukin 1-α on the bioenergetics of RIF-1 tumors. Cancer Res 49: 6379–6382, 1989
Ting L-L, Belfi CA, Tefft M, Ngo FQH: KHT sarcoma blood perfusion change after single-dose X-ray irradiation. Int J Radiat Biol 60: 335–339, 1991
Ausmus PL, Wilke AV, Frazier DL: Effects of hyperthermia on blood flow and cis-diamminedichloroplatinum (II) pharmacokinetics in murine mammary adenocarcinomas. Cancer Res 52: 4965–4968, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steen, R.G., Kitagishi, K. & Morgan, K. In vivo measurement of tumor blood oxygenation by near-infrared spectroscopy: Immediate effects of pentobarbital overdose or carmustine treatment. J Neuro-Oncol 22, 209–220 (1994). https://doi.org/10.1007/BF01052921
Issue Date:
DOI: https://doi.org/10.1007/BF01052921